在RAISE试验中，评分波动可能与较高的安慰剂率相关。 - Suppr | 超能文献

Score fluctuation might be associated with a higher placebo rate in the RAISE trial.

作者信息

Li Hai-Feng, Hu Shi-Min, Yin Jian, Yang Huan

机构信息

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

出版信息

Lancet Neurol. 2023 Nov;22(11):982. doi: 10.1016/S1474-4422(23)00364-2.

DOI:10.1016/S1474-4422(23)00364-2

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Score fluctuation might be associated with a higher placebo rate in the RAISE trial.在RAISE试验中，评分波动可能与较高的安慰剂率相关。

Lancet Neurol. 2023 Nov;22(11):982. doi: 10.1016/S1474-4422(23)00364-2.

2

Early score fluctuation and placebo response in a study of major depressive disorder.研究重性抑郁障碍中的早期评分波动和安慰剂反应。

J Psychiatr Res. 2020 Feb;121:118-125. doi: 10.1016/j.jpsychires.2019.11.014. Epub 2019 Nov 22.

3

Effect of dry needling of gluteal muscles on straight leg raise: a randomised, placebo controlled, double blind trial.臀肌干针疗法对直腿抬高的影响：一项随机、安慰剂对照、双盲试验

Br J Sports Med. 2005 Feb;39(2):84-90. doi: 10.1136/bjsm.2003.009431.

4

A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.一项为期2周的多中心、随机、双盲、安慰剂对照、剂量范围研究的III期试验，比较了羟考酮缓释剂与安慰剂对患有髋部或膝部骨关节炎相关疼痛的成年人的疗效。

Clin Ther. 2006 Mar;28(3):352-64. doi: 10.1016/j.clinthera.2006.03.008.

5

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.在全身性重症肌无力患者中zilucoplan 的安全性和疗效（RAISE）：一项随机、双盲、安慰剂对照、3 期研究。

Lancet Neurol. 2023 May;22(5):395-406. doi: 10.1016/S1474-4422(23)00080-7.

6

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.一项评估维洛沙嗪缓释胶囊治疗成人注意缺陷多动障碍的疗效和安全性的 III 期、随机、双盲、安慰剂对照试验。

CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27.

7

A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.一项双盲、多中心试验，比较度洛西汀与安慰剂治疗伴或不伴重度抑郁症的纤维肌痛患者的疗效。

Arthritis Rheum. 2004 Sep;50(9):2974-84. doi: 10.1002/art.20485.

8

Efficacy and Safety of Once-Daily Controlled-Release Pregabalin for the Treatment of Patients With Postherpetic Neuralgia: A Double-Blind, Enriched Enrollment Randomized Withdrawal, Placebo-Controlled Trial.每日一次缓释普瑞巴林治疗带状疱疹后神经痛患者的疗效和安全性：一项双盲、富集入组随机撤药、安慰剂对照试验。

Clin J Pain. 2017 Jul;33(7):569-578. doi: 10.1097/AJP.0000000000000445.

9

Study of the use of antidepressants for depression in dementia: the HTA-SADD trial--a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine.痴呆患者使用抗抑郁药治疗抑郁症的研究：HTA-SADD 试验——一项多中心、随机、双盲、安慰剂对照研究，旨在评估舍曲林和米氮平的临床疗效和成本效益。

Health Technol Assess. 2013 Feb;17(7):1-166. doi: 10.3310/hta17070.

10

Zinc sulfate as an adjunct to methylphenidate for the treatment of attention deficit hyperactivity disorder in children: a double blind and randomized trial [ISRCTN64132371].硫酸锌作为哌甲酯的辅助药物用于治疗儿童注意力缺陷多动障碍：一项双盲随机试验[国际标准随机对照试验编号64132371]

BMC Psychiatry. 2004 Apr 8;4:9. doi: 10.1186/1471-244X-4-9.

引用本文的文献

1

Risk-Benefit Analysis of Novel Treatments for Patients with Generalized Myasthenia Gravis.新型治疗方案治疗全身性重症肌无力患者的风险效益分析。

Adv Ther. 2024 Dec;41(12):4628-4647. doi: 10.1007/s12325-024-03014-5. Epub 2024 Oct 29.

2

Editorial: Phenotypes of myasthenia gravis, volume II.社论：重症肌无力的表型，第二卷。

Front Neurol. 2023 Nov 24;14:1335308. doi: 10.3389/fneur.2023.1335308. eCollection 2023.